Apixaban does not require monitoring nor frequent dose adjustment. However, searching for
the optimal dose for the individual patient may be useful in some situations. Moreover, there …

A universal anti‐Xa assay for the determination of rivaroxaban, apixaban and edoxaban
drug concentrations would simplify laboratory procedures and facilitate widespread …

While laboratory monitoring is not required in patients treated with apixaban, a direct factor-
Xa inhibitor, assessment of its concentration is useful in some critical situations. However …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …

This issue of Clinical Chemistry and Laboratory Medicine includes a review by Meyer M.
Samama on the laboratory assessment of the new anticoagulant agents (1). This is a timely …

The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has
significantly impacted the treatment and prevention of thromboembolic disease. Clinical …

Introduction The purpose of this study is to compare the effect of increasing concentrations of
direct anti‐Xa oral anticoagulants (DOAC) apixaban‐, edoxaban‐, and rivaroxaban …

Background Three novel direct oral anticoagulants (DOACs) have recently been registered
by the Food and Drug Administration and European Medicines Agency Commission …

New oral anticoagulants are directed towards a single target, essentially factor Xa (FXa) or
factor IIa. They do not require routine coagulation monitoring. However, in special clinical …

We and others have previously highlighted the potential problems with testing of lupus
anticoagulants (LA) in patients on anticoagulant therapy, including most recently as related …